President & CEO
Mr. Parrish is a founder, Director, President and Chief Executive Officer of BioVascular, Inc. He has founded and been founding CEO of two medical device and four pharmaceutical companies, and has over 30 years of medical industry experience. He was previously President/CEO of Angiosyn, Inc. (acquired by Pfizer), Optobionics Corp. (privately held), Valley Forge Pharmaceuticals (privately held), ISTA Pharmaceuticals (publicly held), Intramed Labs. (publicly held), and Vitalmetrics, Inc. (publicly held). Previously he had served IVAC Corp. and Baxter Healthcare in various management positions. He is a member of the Board of Directors of Cardioptics Corp., Valley Forge Pharmaceuticals, and the Discovery Eye Foundation at University of California, Irvine. He holds a B.S. degree in Biology/Chemistry from Wake Forest University, where he served on the schools Board of Visitors.
|
Vice President, Development
Dr. Glidden is a founder, Director and Vice President of Development of BioVascular, Inc. He was previously Vice President, Development of Angiosyn, Inc. In this position, Dr. Glidden was responsible for all Non-clinical, Manufacturing, Regulatory, Quality and Clinical aspects of the T2-TrpRS project. This project was acquired by Pfizer in January 2005 where it continues to be developed for treatment of Age-related Macular Degeneration. Prior to this position, Dr. Glidden was Director of Pharmacology and Toxicology at ISTA Pharmaceuticals. While at ISTA, his work on the NDA for Vitrase, a biologic compound injected into the vitreous cavity of the eye to dissolve a vitreous hemorrhage. From 1989 to 2000, Dr. Glidden was at Alpha Therapeutics developing new chemical entities for cardiovascular therapies, including critical limb ischemia and intermittent claudication, new molecular entities for the treatment of non-Hodgkin’s lymphoma, and blood-derived products for use in surgical maneuvers or as replacement therapy as Manager of Pharmacology. Dr. Glidden holds a B.S. degree in Biochemistry and Biophysics from Oregon State University and a Ph.D. in Pharmacology and Toxicology from University of California, Irvine.
|
Chief Medical Officer, Vice President of Clinical Research & Regulatory Affairs
Dr. Pilgrim has extensive experience in leading the global development of drugs in a wide range of therapeutic areas including cardiology, neurology, psychiatry and inflammation. While at Glaxo she led the clinical program for Imitrex from phase 2-4 and through a series of line extensions. At Sanofi she oversaw the global approval of Plavix and initiated the major megatrials which were key to the successful commercialization of the drug. Dr Pilgrim has experience of leading drug development within both large integrated pharmaceutical companies, such as Glaxo, Sanofi and DuPont and within smaller and virtual companies including Elan, Avera and CoLucid. As a clinical pharmacologist at Beecham Pharmaceuticals she was responsible for a wide range of early clinical studies, including first-in-man, pharmacokinetics and efficacy modeling in healthy subjects. Dr Pilgrim trained as a scientist and physician at Oxford University in the UK, qualifying as a physician and gaining a doctorate in development neurobiology.
|
Vice President of Pharmaceutical Operations
Dr. Bussineau was previously Vice President and General Manager for Cambrex Bio Science Baltimore, a contract development and manufacturing business serving the biotechnology industry. Prior to this position, Dr. Bussineau was Senior Director of Technical Operations for Chiron Corporation’s Biopharmaceutical Division. While at Chiron, he held positions of increasing scientific and managerial responsibility in process development as well as clinical and commercial manufacturing that encompassed strategic planning, facility design, technology transfer, validation, regulatory submissions, quality and safety compliance, and customer relations. Dr. Bussineau holds a PhD in Chemical Engineering from Rice University and a BA in Chemistry (biochem emphasis) from University of California, San Diego.
|
Vice President, Business Development and Nonvascular Operations
Mr. Karpinski has extensive experience in business development, venture financing and strategic planning in the biopharma industry. He joined the company after six years as a venture capitalist with Forward Ventures where he drove the diligence and supported companies in the portfolio including Hypnion (sold to Eli Lilly for $315M), Novacardia (sold to Merck for $350M), Predix (sold to Epix Medical) and Adiana (sold to Cytyc). Prior to Forward, Mr. Karpinski held roles in business development at Genentech, business development and strategic planning at Epix and was an analyst in the pharmaceutical consulting practice of Arthur D. Little. Mr. Karpinski began his career in the laboratories of two biotechnology companies, Novavax and Univax, prior to entering the business side of the life sciences industry. Mr Karpinski holds a Master's Degree in Business Administration from The Wharton School of Business at the University of Pennsylvania and he earned a Bachelor's Degree in Biochemistry from Brown University, where he graduated with honors.
|
Senior Director, Clinical Operations
Ms. Foster has over fifteen years of clinical development industry experience in over 35 clinical trials from Phase I to IV. Ms. Foster has supervised and managed international teams of 250+ personnel, inclusive of investigators, CRO personnel, and the departmental team. She has implemented clinical research protocols, developed and managed all logistics for global trials, established quality methods, and provided project management at all stages of product development. Ms. Foster has experience in preparing regulatory submissions to the FDA and other Regulatory Agencies, inclusive of INDs/CTAs and NDAs. Therapeutic areas of experience have included anti-infective, lupus nephritis, antiphospholipid syndrome (thrombosis), various CNS disorders, psoriasis, Alzheimer’s disease, and male erectile dysfunction. Ms. Foster was previously employed at La Jolla Pharmaceutical Company (Sr. Director, Clinical Operations) from 2000 to 2005. Prior, Ms. Foster held positions of increasing responsibility at two of the largest international CROs, Quintiles, Inc and PAREXEL International. Ms. Foster holds her B.S. degree from Michigan State University, her M.A. in Organizational Management from University of Phoenix, and has U.S. Regulatory Affairs Certification designation.
|
